Saxony Focuses on Precision Medicine
SaxoCell, the Saxon cluster for precision medicine, wants to become an international leader in innovative cell and gene therapeutics. Towards this end, the network, an alliance of leading research institutes and medical facilities from Leipzig, Dresden, and Chemnitz as well as national enterprises, is working, for
example, on specific projects which are designed to optimise the CAR-T cell therapy and adapt it for use in other therapies.
AI in diagnostics
In Dresden, experts from the National Center for Tumor Diseases (NCT), the National Center for Radiation Research in Oncology (OncoRay), the German Consortium for Translational Cancer Research (DKTK), and the Else Kröner Fresenius Center for Digital Health (EKFZ) are investigating new therapies for cancer and tumor treatment by pursuing different approaches and research methods. The institutes’ research activities are geared towards the application of artificial intelligence for the evaluation and interpretation of complex image data and the application of high-precision radiation therapies with a specific focus on particle and proton therapy. The Dresden University of Technology's (TU Dresden) new degree programs in Biomedical Engineering and Medical Informatics both heavily incorporate artificial intelligence in medicine as a pioneering scientific field.
New diagnostic approaches and methods for fighting cancer raise the demand for so-called radiopharmaceuticals. The new Saxon “Radiopharmaceutical Valley” seeks to close this gap with innovative solutions. It is a highly specialised niche in which such companies as Rotop Pharmaka, ABX advanced biochemical compounds, and TRIMT as well as the CUP Laboratories Radeberg are active together with the research center Helmholtz-Zentrum Dresden-Rossendorf (HZDR). The new clinical area of application of “theranostics” combines molecular imaging with radioligand therapy. It is currently evolving into one of the most promising targeted therapies with surprisingly low side effects.
Innovative analysis methods
The Molecular Diagnostics Group (MDG), which consists of the three companies BIOTYPE (molecular precision diagnostics), qualitype (software & data) as well as Rotop Pharmaka (molecular imaging), develops and promotes innovative analysis methods and diagnostics for precision medicine. Coordinated from Dresden, MDG is developing a number of innovative cancer diagnostics in strategic partnerships at a national and international level.
When it comes to precision medicine, an innovative ecosystem has emerged in Saxony which offers a very attractive environment not only for cooperations, and new business partners, but also for startups and business setups. Saxony Trade & Invest is happy to be your contact for this.
Saxony Trade & Invest
Wirtschaftsförderung Sachsen GmbH (WFS)